Chimeric antigen receptor T-cell therapy to target hematologic malignancies

Saad Kenderian, Marco Ruella, Saar Gill, Michael Kalos

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificity of antibodies with the polyfunctionality and potency of cellular immunity and are a prime example of the potential for synthetic biology to treat disease. CAR T cells overcome several of the biologic obstacles that have historically hampered immunotherapy while providing fundamental mechanistic insights into cellular immunology and revealing new challenges in genetic engineering and target selection. Results from early-phase CAR T-cell-based clinical trials demonstrate the significant potential for this approach to affect dramatic and complete clinical responses while revealing novel toxicities associated with activation of potent and specific antitumor immunity.

Original languageEnglish (US)
Pages (from-to)6383-6389
Number of pages7
JournalCancer Research
Volume74
Issue number22
DOIs
StatePublished - Nov 15 2014

Fingerprint

Antigen Receptors
Hematologic Neoplasms
Cell- and Tissue-Based Therapy
Immunotherapy
T-Cell Antigen Receptor
Synthetic Biology
T-Lymphocytes
Genetic Engineering
Antibody Specificity
Cell Transplantation
Allergy and Immunology
Cellular Immunity
Immunity
Monoclonal Antibodies
Clinical Trials
Antigens
Antibodies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Chimeric antigen receptor T-cell therapy to target hematologic malignancies. / Kenderian, Saad; Ruella, Marco; Gill, Saar; Kalos, Michael.

In: Cancer Research, Vol. 74, No. 22, 15.11.2014, p. 6383-6389.

Research output: Contribution to journalReview article

Kenderian, Saad ; Ruella, Marco ; Gill, Saar ; Kalos, Michael. / Chimeric antigen receptor T-cell therapy to target hematologic malignancies. In: Cancer Research. 2014 ; Vol. 74, No. 22. pp. 6383-6389.
@article{a2c2f34f4b6641c0a9bf878fc67a0650,
title = "Chimeric antigen receptor T-cell therapy to target hematologic malignancies",
abstract = "Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificity of antibodies with the polyfunctionality and potency of cellular immunity and are a prime example of the potential for synthetic biology to treat disease. CAR T cells overcome several of the biologic obstacles that have historically hampered immunotherapy while providing fundamental mechanistic insights into cellular immunology and revealing new challenges in genetic engineering and target selection. Results from early-phase CAR T-cell-based clinical trials demonstrate the significant potential for this approach to affect dramatic and complete clinical responses while revealing novel toxicities associated with activation of potent and specific antitumor immunity.",
author = "Saad Kenderian and Marco Ruella and Saar Gill and Michael Kalos",
year = "2014",
month = "11",
day = "15",
doi = "10.1158/0008-5472.CAN-14-1530",
language = "English (US)",
volume = "74",
pages = "6383--6389",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "22",

}

TY - JOUR

T1 - Chimeric antigen receptor T-cell therapy to target hematologic malignancies

AU - Kenderian, Saad

AU - Ruella, Marco

AU - Gill, Saar

AU - Kalos, Michael

PY - 2014/11/15

Y1 - 2014/11/15

N2 - Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificity of antibodies with the polyfunctionality and potency of cellular immunity and are a prime example of the potential for synthetic biology to treat disease. CAR T cells overcome several of the biologic obstacles that have historically hampered immunotherapy while providing fundamental mechanistic insights into cellular immunology and revealing new challenges in genetic engineering and target selection. Results from early-phase CAR T-cell-based clinical trials demonstrate the significant potential for this approach to affect dramatic and complete clinical responses while revealing novel toxicities associated with activation of potent and specific antitumor immunity.

AB - Several decades of humoral immunotherapy using monoclonal antibodies and cellular immunotherapy using hematopoietic cell transplantation have recently culminated in a successful merger: the development and clinical application of genetically engineered antibody-T cell chimeras. Also known as chimeric antigen receptor T cells (CAR T cells), these entities combine the exquisite antigen specificity of antibodies with the polyfunctionality and potency of cellular immunity and are a prime example of the potential for synthetic biology to treat disease. CAR T cells overcome several of the biologic obstacles that have historically hampered immunotherapy while providing fundamental mechanistic insights into cellular immunology and revealing new challenges in genetic engineering and target selection. Results from early-phase CAR T-cell-based clinical trials demonstrate the significant potential for this approach to affect dramatic and complete clinical responses while revealing novel toxicities associated with activation of potent and specific antitumor immunity.

UR - http://www.scopus.com/inward/record.url?scp=84918558415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918558415&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-1530

DO - 10.1158/0008-5472.CAN-14-1530

M3 - Review article

C2 - 25371415

AN - SCOPUS:84918558415

VL - 74

SP - 6383

EP - 6389

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 22

ER -